PBAC’s pricing model for HTAs ‘penalises innovation’

4 minute read


Pharma giants Bayer and Theramex say current frameworks disincentivise companies from submitting new HRT and MHT products to the PBAC.


Pharma giants Bayer and Theramex say current frameworks disincentivise companies from submitting new HRT and MHT products to the PBAC.

This content is for Health Services Daily members only.
or Join Now.

End of content

No more pages to load

Log In Register ×